DK116943B - Fremgangsmåde til fremstilling af (3-amino-5,6-disubstituerede-pyrazinoyl)-guanidinforbindelser eller syreadditionssalte deraf. - Google Patents

Fremgangsmåde til fremstilling af (3-amino-5,6-disubstituerede-pyrazinoyl)-guanidinforbindelser eller syreadditionssalte deraf.

Info

Publication number
DK116943B
DK116943B DK453364AA DK453364A DK116943B DK 116943 B DK116943 B DK 116943B DK 453364A A DK453364A A DK 453364AA DK 453364 A DK453364 A DK 453364A DK 116943 B DK116943 B DK 116943B
Authority
DK
Denmark
Prior art keywords
pyrazinoyl
disubstituted
amino
preparation
acid addition
Prior art date
Application number
DK453364AA
Other languages
English (en)
Inventor
E Cragoe
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of DK116943B publication Critical patent/DK116943B/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK453364AA 1962-10-30 1964-09-14 Fremgangsmåde til fremstilling af (3-amino-5,6-disubstituerede-pyrazinoyl)-guanidinforbindelser eller syreadditionssalte deraf. DK116943B (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23423062A 1962-10-30 1962-10-30
US313315A US3313813A (en) 1962-10-30 1963-10-07 (3-amino-5, 6-disubstituted-pyrazinoyl) guanidines

Publications (1)

Publication Number Publication Date
DK116943B true DK116943B (da) 1970-03-02

Family

ID=26927694

Family Applications (4)

Application Number Title Priority Date Filing Date
DK512263AA DK114978B (da) 1962-10-30 1963-10-30 Fremgangsmåde til fremstilling af (3-amino-pyrazinoyl)-guanidin-forbindelser eller salte heraf.
DK453364AA DK116943B (da) 1962-10-30 1964-09-14 Fremgangsmåde til fremstilling af (3-amino-5,6-disubstituerede-pyrazinoyl)-guanidinforbindelser eller syreadditionssalte deraf.
DK619865AA DK114557B (da) 1962-10-30 1965-12-02 Fremgangsmåde til fremstilling af pteridin-forbindelser.
DK619765AA DK115403B (da) 1962-10-30 1965-12-02 Fremgangsmåde til fremstilling af (3-amino-pyrazinoyl)-guanidiner.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK512263AA DK114978B (da) 1962-10-30 1963-10-30 Fremgangsmåde til fremstilling af (3-amino-pyrazinoyl)-guanidin-forbindelser eller salte heraf.

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK619865AA DK114557B (da) 1962-10-30 1965-12-02 Fremgangsmåde til fremstilling af pteridin-forbindelser.
DK619765AA DK115403B (da) 1962-10-30 1965-12-02 Fremgangsmåde til fremstilling af (3-amino-pyrazinoyl)-guanidiner.

Country Status (13)

Country Link
US (1) US3313813A (da)
BE (1) BE639386A (da)
BR (1) BR6354164D0 (da)
CH (1) CH465617A (da)
CY (1) CY440A (da)
DE (2) DE1470053A1 (da)
DK (4) DK114978B (da)
FI (1) FI47102C (da)
FR (1) FR1563612A (da)
GB (1) GB1066855A (da)
MY (1) MY6900026A (da)
NL (2) NL142413B (da)
SE (1) SE321230B (da)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6409714A (da) * 1962-10-30 1965-10-01
US3472848A (en) * 1966-11-17 1969-10-14 Merck & Co Inc 3-hydroxy and 3-mercapto-pyrazinoyl-guanidines,corresponding ethers and thioethers and processes for their preparation
US3948895A (en) * 1971-09-28 1976-04-06 E. I. Du Pont De Nemours And Company Synthesis of 3,5-diaminopyrazinoic acid from 3,5-diamino-2,6-dicyanopyrazine and intermediates
US4085211A (en) * 1975-12-15 1978-04-18 Merck & Co., Inc. Pyrazinecarboxamides and processes for preparing same
US4087526A (en) * 1976-07-23 1978-05-02 Merck & Co., Inc. (3-Amino-5-substituted-6-fluoropyrazinoyl or pyrazamido)-guanidines and their derivatives bearing substituents on the guanidino nitrogens
US4208413A (en) * 1977-03-04 1980-06-17 Merck & Co., Inc. N-Pyrazinecarbonyl-N'-alkoxycarbonyl and N',N"-bis(alkoxycarbonyl)guanidines and processes for preparing same
US4108859A (en) * 1977-06-06 1978-08-22 The Dow Chemical Company Microbicidal (pyridinylamino) alkyl guanidines
US4140776A (en) * 1977-09-16 1979-02-20 Merck & Co., Inc. N-pyrazinecarbonyl-N'-acylguanidines
US4190655A (en) * 1978-08-28 1980-02-26 Merck & Co., Inc. Amiloride citrate
EP0009054A1 (en) * 1978-09-19 1980-04-02 Merck & Co. Inc. N-Pyrazinecarbonyl-N'-substituted-sulfamoyl-guanidine and processes for preparing same
US4246406A (en) * 1979-03-27 1981-01-20 Merck & Co., Inc. Heterocyclic substituted pyrazinoylguanidines
US4224447A (en) * 1979-03-27 1980-09-23 Merck & Co., Inc. Novel pyrazinecarboxamides and processes for preparing same
US4362724A (en) * 1980-05-19 1982-12-07 Merck & Co., Inc. Method of treating edema and hypertension and pharmaceutical composition therefor in which the active ingredient comprises a novel substituted pyrazinyl-1,2,4-oxadiazole and a kaliuretic diuretic
US4309540A (en) * 1980-05-19 1982-01-05 Merck & Co., Inc. Substituted pyrazinyl-1,2,4-oxadiazoles
US4454132A (en) * 1981-03-16 1984-06-12 Merck & Co., Inc. Pharmaceutical compositions of novel substituted pyrazinyl-1,2,4-oxadiazoles useful in the treatment of edema and hypertension
US4510322A (en) * 1981-07-13 1985-04-09 Merck & Co., Inc. Indacrinone having enhanced uricosuric
US4952582A (en) * 1982-01-04 1990-08-28 Beyer Jr Karl H Pyrazinoylguanidine and derivatives thereof having few polar substituents and being useful as hyperuretic agents
US4663322A (en) * 1982-01-04 1987-05-05 Beyer Jr Karl H Antihypertensive hyperuretic and saluretic agent combinations
DE3312516A1 (de) * 1983-04-07 1984-10-11 Brigitte Dr. 7400 Tübingen Pfeiffer Kernsubstituierte phenylalkylenguanidinderivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
US4604394A (en) * 1984-10-01 1986-08-05 Merck & Co., Inc. Antiarrhythmic compositions and method
DE3925847A1 (de) * 1989-08-04 1991-02-07 Huels Chemische Werke Ag Verfahren zur herstellung von 3-aminopyrazin-2-carbonsaeuremethylester
US5304125A (en) * 1990-10-05 1994-04-19 The University Of North Carolina Apparatus for administering solid particulate aerosols to the lungs
WO1992005779A1 (en) * 1990-10-05 1992-04-16 The University Of North Carolina At Chapel Hill Method of administering amiloride
TW213903B (da) * 1991-08-16 1993-10-01 Boehringer Ingelheim Kg
US6169107B1 (en) 1993-04-28 2001-01-02 Sumitomo Pharmaceutical Co., Ltd. Indoloylguanidine derivatives
DE4337609A1 (de) * 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Pyrazincarboxamidderivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
US5656256A (en) * 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
TW372967B (en) * 1994-12-27 1999-11-01 Kanebo Ltd 1,4 benzoxazine derivative, pharmaceutical composition containing the same and use thereof
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5628984A (en) 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
US5801177A (en) * 1995-12-14 1998-09-01 Beyer, Jr.; Karl H. Method for controlling and/or lowering serum glucose and fatty acid concentrations and hypertensive blood pressure in non-insulin-dependent diabetic patients
US5877217A (en) * 1995-12-26 1999-03-02 Alteon Inc. N-acylaminoalkyl-hydrazinecarboximidamides
CA2300146A1 (en) * 1997-08-29 1999-03-04 Richard C. Boucher, Jr. Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases
AU757139B2 (en) * 1998-10-20 2003-02-06 University Of North Carolina At Chapel Hill, The Methods of hydrating mucosal surfaces
EP1161242A4 (en) * 1999-01-29 2004-06-30 Beyer Camille F COMPOSITION AND METHOD FOR TREATING DIABETES
CA2378181A1 (en) 1999-07-19 2001-01-25 Richard C. Boucher, Jr. Conjugates of sodium channel blockers and methods of using the same
NZ525913A (en) 2000-11-21 2004-05-28 Sankyo Co A pharmaceutical composition
US6858615B2 (en) * 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US6858614B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenolic guanidine sodium channel blockers
US7704995B2 (en) * 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
CA2484209C (en) * 2002-05-03 2013-06-11 Exelixis, Inc. Protein kinase modulators and methods of use
CN1681495B (zh) 2002-08-19 2010-05-12 辉瑞产品公司 用于治疗过度增生性疾病的组合物
US6903105B2 (en) * 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
AU2004248859C1 (en) * 2003-06-26 2011-11-24 Biotron Limited Antiviral acylguanidine compounds and methods
EP2617709B8 (en) 2003-06-26 2022-12-21 Biotron Limited Guanidine derivatives as antiviral agents
US7326706B2 (en) * 2003-08-15 2008-02-05 Bristol-Myers Squibb Company Pyrazine modulators of cannabinoid receptors
WO2005018644A1 (en) 2003-08-18 2005-03-03 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
EP1670475A4 (en) * 2003-08-18 2009-04-15 Parion Sciences Inc ALAPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS
US20050090505A1 (en) * 2003-08-18 2005-04-28 Johnson Michael R. Methods of reducing risk of infection from pathogens
US20090253714A1 (en) * 2003-08-20 2009-10-08 Johnson Michael R Methods of reducing risk of infection from pathogens
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US20070099968A1 (en) * 2004-06-26 2007-05-03 Biotron Limited Antiviral compounds and methods
US20070021439A1 (en) * 2005-07-25 2007-01-25 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
WO2007062222A2 (en) * 2005-11-22 2007-05-31 University Of South Florida Inhibition of cell proliferation
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
ES2382009T3 (es) 2006-12-01 2012-06-04 Bristol-Myers Squibb Company Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
AU2008310734B2 (en) * 2007-10-10 2014-06-05 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
MX344703B (es) 2008-02-26 2017-01-03 Parion Sciences Inc Bloqueadores de canal de sodio poliaromaticos.
DE102008053024B4 (de) 2008-10-24 2015-04-30 RUHR-UNIVERSITäT BOCHUM Verwendung von Amilorid-Derivaten zur Bekämpfung von Insekten und Milben
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
ES2633177T3 (es) 2011-06-27 2017-09-19 Parion Sciences, Inc. Dipéptido química y metabólicamente estable que presenta una potente actividad bloqueadora de los canales de sodio
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
JP6272312B2 (ja) 2012-05-29 2018-01-31 パリオン・サイエンシィズ・インコーポレーテッド ドライアイおよび他の粘膜疾患の治療のためのナトリウムチャネル遮断活性を有するデンドリマー様アミノアミド
WO2014099676A1 (en) 2012-12-17 2014-06-26 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
EP3428153A1 (en) 2012-12-17 2019-01-16 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
JP2016516804A (ja) 2013-04-17 2016-06-09 ファイザー・インク 心血管疾患を治療するためのｎ−ピペリジン−３−イルベンズアミド誘導体
WO2015003958A1 (en) * 2013-07-08 2015-01-15 Boehringer Ingelheim International Gmbh Amiloride-type compounds as inhibitors in epithelial sodium channels for the treatment of diseases of the lungs and airways
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CN109476599A (zh) * 2016-07-29 2019-03-15 东丽株式会社 胍衍生物和其医药用途
EP3911648A4 (en) 2019-01-18 2022-10-26 Astrazeneca AB PCSK9 INHIBITORS AND METHODS OF USE THEREOF

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL299929A (da) * 1962-10-30

Also Published As

Publication number Publication date
DE1795438B1 (de) 1973-09-06
CH465617A (de) 1968-11-30
NL142413B (nl) 1974-06-17
DK114978B (da) 1969-08-25
DE1795438C2 (de) 1974-04-11
US3313813A (en) 1967-04-11
FI47102C (fi) 1973-09-10
SE321230B (da) 1970-03-02
FI47102B (da) 1973-05-31
DK115403B (da) 1969-10-06
MY6900026A (en) 1969-12-31
BE639386A (da)
FR1563612A (da) 1969-04-18
DE1470053A1 (de) 1969-06-26
NL299931A (da)
DK114557B (da) 1969-07-14
GB1066855A (en) 1967-04-26
BR6354164D0 (pt) 1973-09-18
CY440A (en) 1968-05-18

Similar Documents

Publication Publication Date Title
DK116943B (da) Fremgangsmåde til fremstilling af (3-amino-5,6-disubstituerede-pyrazinoyl)-guanidinforbindelser eller syreadditionssalte deraf.
DK107029C (da) Fremgangsmåde til fremstilling af substituerede 2-arylamino-1,3-diazacycloalkener eller syreadditionssalte deraf.
DK108497C (da) Fremgangsmåde til fremstilling af substituerede 6,7-benzomorphaner eller syreadditionssalte deraf.
DK107024C (da) Fremgangsmåde til fremstilling af 4-amino-6,7-dialkoxykinoliner eller syreadditionssalte deraf.
DK108310C (da) Fremgangsmåde til fremstilling af (3-aminopyrazinamido)-guanidinforbindelser eller syreadditionssalte heraf.
DK114903B (da) Fremgangsmåde til fremstilling af 9,10-dihydro-ergovalin eller syreadditionssalte heraf.
DK107354C (da) Fremgangsmåde til fremstilling af 2-guanidinoalkyl-1,4-benzodioxanforbindelser eller syreadditionssalte heraf.
DK109037C (da) Fremgangsmåde til fremstilling af 2-alkyl-3-hydroxy-4,5-di-hydroxymethyl-pyridiner eller syreadditionssalte deraf.
DK109779C (da) Fremgangsmåde til fremstilling af 3-aminopyrazinamidoguanidinforbindelser eller syreadditionssalte heraf.
DK117000B (da) Fremgangsmåde til fremstilling af substituerede phenylamino-1,3-diazacyclopentener-(2) eller syreadditionssalte heraf.
DK112872B (da) Fremgangsmåde til fremstilling af [1,2-α]-imidazopyridiner eller syreadditionssalte deraf.
DK109453C (da) Fremgangsmåde til fremstilling af N,N'-substituerede diaminoethanforbindelser eller syreadditionssalte deraf.
DK127507B (da) Analogifremgangsmåde til fremstilling af 1,4-benzodiazepinforbindelser eller syreadditionssalte deraf.
DK117147B (da) Fremgangsmåde til fremstilling af (3-aminopyrazinoyl)-guanidinforbindelser eller syreadditionssalte deraf.
DK115994B (da) Fremgangsmåde til fremstilling af (3,5-diamino-6-halogenpyrazinoyl)-guanidin- eller (3,5-diamino-6-halogenpyrazinamido)-guanidinforbindelser eller syreadditionssalte deraf.
DK101976C (da) Fremgangsmåde til fremstilling af 1,2,3,4,4a,5,6,10b-octahydro-phenanthridinforbindelser eller syreadditionssalte deraf.
DK105025C (da) Fremgangsmåde til fremstilling af umættede 9,10-dihydro-10,10,-dimethylanthracenderivater eller syreadditionssalte deraf.
DK106381C (da) Fremgangsmåde til fremstilling af 2-dimethylamino-3,5,6-trimethylpyrazin eller syreadditionssalte heraf.
DK119205C (da) Fremgangsmåde til fremstilling af halogenholdige, basisk substituerede dibenzocycloheptatrienforbindelser eller syreadditionssalte deraf.
DK106229C (da) Fremgangsmåde til fremstilling af 1,4-benzo-diazepin-4-oxider eller syreadditionssalte deraf.
DK102917C (da) Fremgangsmåde til fremstilling af basisk substituerede 1,2,3,4-tetrahydro-iso-quinolinderivater eller syreadditionssalte deraf.
DK113651B (da) Fremgangsmåde til fremstilling af 6,11-dihydro-11-(3-alkylaminopropyl)-dibenzo-[b,e]thiepiner eller syreadditionssalte deraf.
DK106380C (da) Fremgangsmåde til fremstilling af basisk substituerede 11-alkyl-5,6-dihydro-6-oxo-morphanthridiner eller syreadditionssalte deraf.
DK105156C (da) Fremgangsmåde til fremstilling af 18,20-lactonen af 3-methylamino-16α,20-dihydroxy-5(6)-pregnen-18-syre of 18,20-lactonen af 3-dimethylamino-16α,20-dihydroxy-5(6)-pregnen-18-syre eller syreadditionssalte heraf.
DK101000C (da) Fremgangsmåde til fremstilling af pyrazinforbindelser eller syreadditionssalte deraf.